ESMO 2020: Positive progress has been made in the treatment of relapsed cervical cancer with antibody-drug couple Tisotumab vedotin.

Cervical cancer is formed inside the cervix that connects the vagina to the uterus.
of cervical cancer is slow and often takes many years to develop.
pharmaceutical company Genmab announced today that positive results have been obtained in the innovaTV 204 study evaluating the treatment of relapsed or metastatic cervical cancer in Tisotumab vedotin, which Genmab will present at the European Society of Medical Oncology (ESMO) in 2020.
Tisotumab vedotin is a research antibody-drug coupled (ADC) consisting of all-human monoclonal antibodies and Seattle Genetics' ADC technology, which uses protease-lysed joint co-priced connection microcosm destroyer vedotin, which induces the death of target cells.
in cancer biology, tissue factors are proteins that promote tumor growth, angiogenesy, and tumor cell metastasis.
based on the high expression of tissue factors in many solid tumors, tissue factors have been used for anti-tumor targets.
Tisotumab vedotin was developed jointly by Genmab and Seattle Genetics, under which the two companies will share all costs and profits of the product.
Van de Winkel, chief executive of Genmab, said: "Despite progress in standard care, treatment options for advanced cervical cancer remain unsolved.
Genmab and Seattle Genetics will work together to develop new treatments for advanced cervical cancer."
Tisotumab vedotin is being used as a monotherapy or in combination with a variety of commonly used therapies to treat a range of solid tumors as well as relapse and/or metastatic cervical cancer.
.